Professor of Medicine, UCSF
Oncology
Dr. Eric J. Small, MD
|
|
Give Review
Dr. Eric J. Small practices Oncology. He researched medicine at Case Western Reserve University School of Medicine. He over the years received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Eric J. Small, MD has written publications. He has 100 publications published with PubMed. The lastest paper is: 'Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.' He is registered with Medicare and accepts Medicare payments.
Publications
- Prospects for the use of ipilimumab in treating advanced prostate Cancer.
- Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
- A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).
- Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Stu...
- Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate Cancer (COU-AA-302): final o...
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results.
- Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Can...
- Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate Cancer treated on Cancer and Leukemia Group ...
- Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate Cancer.
- Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate Cancer and the predictive value of circulatin...
- Can Targeting the Androgen Receptor in Localized Prostate Cancer Provide Insights Into Why Men With Metastatic Castration-Resistant Prostate Cancer Die?
- A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T.
- Reply to F. Valcamonico et al.
- Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.
- Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate Cancer treated with sipuleucel-T.
- Neuroendocrine prostate Cancer: subtypes, biology, and clinical outcomes.
- Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment.
- Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
- Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal Cell carcinoma.
- Prostate Cancer, version 1.2014.
- Prognostic model predicting metastatic castration-resistant prostate Cancer survival in men treated with second-line chemotherapy.
- Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate Cancer treated with second-line chemotherapy.
- Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate.
- Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial.
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate Cancer: Resu...
- Is there a role for immune checkpoint blockade with ipilimumab in prostate Cancer?
- Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy.
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
- Abiraterone in metastatic prostate Cancer without previous chemotherapy.
- Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients.
- The future of Cancer treatment: will it include immunotherapy?
- A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive Prostate ...
- Prostate Cancer: Evolution or Revolution?
- Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate Cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defen...
- Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate Cancer displaying bone flare discordant with serologic response.
- A phase 1 study of everolimus and sorafenib for metastatic clear Cell renal Cell carcinoma.
- Effect of the somatostatin Analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resist...
- Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal Cell carcinoma: final results of CALGB 90206.
- Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate Cancer who received pr...
- Developing immunotherapy as legitimate therapy for patients with prostate Cancer.
- The mechanism of action of estrogen in castration-resistant prostate Cancer: clues from hormone levels.
- A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate Cancer.
- Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate Cancer previously treated with docetaxel-based the...
- Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate Cancer.
- Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate Cancer: data from Southwest Oncology Group Trials 9346 (Intergroup...
- Immunotherapeutics in development for prostate Cancer.
- Potentiating endogenous antitumor immunity to prostate Cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
- Department of Defense prostate Cancer clinical trials consortium: a new instrument for prostate Cancer clinical research.
- Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal Cell carcinoma: CALGB 90206.
- Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for Cancer treatment.
- Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate Cancer: an initial report of CALGB 99...
- Treatment of biochemical recurrence of prostate Cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
- von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear Cell renal Cell carcinoma.
- Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate Cancer.
- CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T Cells in a dose-dependent fashion.
- Pain predicts overall survival in men with metastatic castration-refractory prostate Cancer.
- Prostate Cancer update: 2007.
- Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate Cancer: effect of extent of disease on outcome.
- Management of hormone refractory prostate Cancer.
- Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate Cancer.
- Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone...
- Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate Cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and ...
- Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate Cancer.
- A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate Cancer.
- Immunotherapy for prostate Cancer.
- Prostate Cancer update: 2006.
- Adrenal androgen levels as predictors of outcome in prostate Cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a Cancer and leukemia...
- A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate Cancer.
- Expression of insulin-like growth factor-1 receptor in local and metastatic prostate Cancer.
- The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled Analysis of 9 Cancer and Leukemia Group B Trials.
- Telephone monitoring of distress in patients aged 65 years or older with advanced stage Cancer: a Cancer and leukemia group B study.
- The case for secondary hormonal therapies in the chemotherapy age.
- High risk biochemical relapse and the timing of androgen deprivation therapy.
- Immunotherapy for prostate Cancer using prostatic acid phosphatase loaded antigen presenting cells.
- Reduced incidence of bony metastasis at initial prostate Cancer diagnosis: data from CaPSURE.
- A phase I trial of intravenous CG7870, a replication-selective, Prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metas...
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate Cancer.
- Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled Analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
- Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting Cells (provenge) plus bevacizumab in patients with serologic progression of prostat...
- Clinical and immunological characteristics of patients with serologic progression of prostate Cancer achieving long-term disease control with granulocyte-macrophage co...
- Activities and accomplishments of the Cancer and leukemia group B genitourinary committee.
- Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate Cancer: history and rationale.
- Prostate Cancer update: 2005.
- Evaluation of Prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
- Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate Cancer: results from Cancer a...
- Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal Cell carcinoma.
- A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate Carcinoma: second line taxane-based therapy after first-line epothilone-...
- Prostate Cancer immunology: biology, therapeutics, and challenges.
- Early versus delayed androgen deprivation for prostate Cancer: new fuel for an old debate.
- Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional Cell carcinoma: a Southwest Oncology Group study.
- Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate Cancer.
- Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate Cancer treated in Cancer and Leukemia Group B 9480 study.
- Update on chemotherapy for advanced bladder Cancer.
- Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate Cancer.
- A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional Cell carcinoma.
- Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate Cancer.
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
Schools
Case Western Reserve University School of Medicine
Beth Israel Hospital
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
UCSF -
Beth Israel Deaconess Medical Center -
Case Western Reserve University School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Collin M. Blakely, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea L. Harzstark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle E. Melisko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zane D. Amenhotep, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chloe Atreya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wolfgang M. Korn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Curt A. Ries, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Pourdehnad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Willis H. Navarro, MD
This Doctor is OpenDoctor Recommended.
|